Rigshospitalet
Copenhagen, 2100, Denmark
Location status: Recruiting
Location contact
Mary Jarden, Professor
CONTACT
Mette Schaufuss Engedal, MSc
CONTACT
NCT Number: NCT06281496
A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Copenhagen, 2100, Denmark
Location status: Recruiting
Mary Jarden, Professor
CONTACT
Mette Schaufuss Engedal, MSc
CONTACT
The study aims to investigate the effect of a stepped care intervention in allo-HSCT survivors on health-related quality of life and late effects.
Method:
This study is designed as a one-site, two-arm prospective randomized controlled trial proceeding an internal pilot phase.
Population/recruitment:
Recruitment, inclusion, and exclusion criteria as described in the eligibility section. Included patients will be randomized and allocated 1:1 to an intervention group or a control group.
Intervention:
a stepped-care multi-modal intervention
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Survivorship supportive care
Time frame: 15 months (baseline 3, post intervention 12 and follow-up 18 month after treatment with allogeneic stem cell transplantation)
Between-group changes in Quality of life - from baseline 3 months post treatment with allogenenic stem cell transplantation to postintervention 12 months post treatment with allogeneic stem cell transplantation. EORTC Quality of Life core questionnaire (QLQ-C30). The EORTC QoL Core Questionnaire EORTC QLQ-C30 is a 30-item instrument designed to measure quality of life in all cancer patients. The questionnaire consists of five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea and vomiting), a global health status / QoL scale, and some single items assessing additional symptoms commonly reported by cancer patients
Time frame: 15 months (baseline 3, post intervention 12 and follow up 18 month after treatment with allogeneic stem cell transplantation)
EORTC-QOL-SURV100, Quality of life questionnaire applicable to cancerfree survivors. It consists of 100 questions divided over thirteen functional scales (i.e. Physical; Role ; Emotional; and Cognitive functioning; Body image; Symptom awareness; Positive health behavior change; Positive life outlook; Positive impact on behavior towards others; Positive social functioning; Work; Sexual functioning; Global health status), nine symptom scales (i.e. Social isolation; Fatigue; Pain; Sleep problems; Health distress; Negative health outlook; Social interference; Sexual problems), one Symptom checklist assessing chronic side effects of cancer treatments, and twelve single items.
Score from 0 to 100. A high score for a functional scale represents a high/healthy level of functioning, a high score for the global health status/QL represents a high QL, but a high score for a symptom item represents a high level of symptomatology.
Time frame: 15 months (baseline 3, post intervention 12 and follow up 18 month after treatment with allogeneic stem cell transplantation)
The survey encompasses nine separate scales exploring 9 different domains of health literacy. The following health literacy domains have been chosen; Scale 1: Feeling understood and supported by health care providers. Scale 3: Actively managing my health. Scale 8: Ability to find good health information and finally Scale 9: Understanding health information well enough to know what to do. The scales can be used individually as no summary score of total health literacy can be measured.
Time frame: 15 months (baseline 3, post intervention 12 and follow up 18 month after treatment with allogeneic stem cell transplantation)
Municipal rehabilitation adresses both physical rehabilitation as well as psychosocial and work related problems based on disease and cancer treatment.
Time frame: 15 months (baseline 3, post intervention 12 and follow up 18 month after treatment with allogeneic stem cell transplantation)
Validated questionnaire to measure degree of Graft Versus Host disease. The scale contains 28 items grouped in 7 subscales (skin, eye, mouth, lung, nutrition, energy, and psychological), and a 7 day recall period. Patients report how "bothered" they feel about each symptom over the previous 7 days using a five-point Likert scale from "not at all" to "extremely". range from 0 to 100, with a higher score indicating worse symptoms
Contact information is provided by the study sponsor or research team.
Mary Jarden
CONTACT
Mette Schaufuss Engedal, MSc
CONTACT
Rigshospitalet, Denmark
Other
Acronym: AlloCare
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05329649
Anemia, Anemia, Hemolytic
Charlotte, North Carolina, United States
View Trial DetailsNCT05041933
Hematologic Diseases, Hematological Diseases
Limoges, France
View Trial DetailsNCT06277479
Hematologic Diseases, Hematological Diseases
Copenhagen, Denmark
View Trial DetailsNCT03745287
Anemia, Anemia, Hemolytic
Palo Alto, California, United States
View Trial Details